I understand Stups, some whos first language is French may have trouble understanding the presentation and wording used in the NR.
What management is presenting, are separte events in a bulleted list.
Listed point 1 is the "anticipated filing of BLA". No guarantee, management is anticipating its sumbmission. Definition of anticipated - "regard as probable; predict.". Remember, they haven't got the FDA required checks in place and its been two years.
Listed point 2, "expected completion" of partnership. No guarantee of a partnership they are hopeful to get a deal.
Also, you failed to highlight the most critical part of point 2; "if approval received". Management is stating a partnership is hopeful; if the FDA approval is received.
Point 1 is a separate event, ie filing BLA.
Point 2 is another event, totally separate from the first.
Key Corporate and R&D Priorities for 2020
- Anticipated filing of an amended BLA with FDA for Ryplazim for the treatment of congenital plasminogen deficiency in the first half of the year
- Expected completion of a global marketing partnership for Ryplazim, and preparation for commercial launch of Ryplazim in the United States, if approval is received